Zomedica Strengthens Executive Leadership Team

ANN ARBOR, Mich., July 10, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V: ZOM ), a veterinary pharmaceutical and health care solutions company, today announced that Bruk Herbst has joined the company as Chief Commercial Officer. In this new company position, he is responsible for delivering and executing Zomedica’s commercial strategy, as well as leading the company’s business groups across multiple functional areas, including sales, marketing, and customer support and service operations.

“Bruk’s expertise and insights are a distinct advantage as we prepare to transition from a research and development only company to commercial readiness,” stated Gerald Solensky Jr., Chief Executive Officer at Zomedica. “He has an acute understanding of the veterinary market and makes a welcome addition to our leadership team.”

Herbst brings with him more than 20 years of experience leading commercial strategies to drive sales, marketing, support and technical teams to achieve accelerated revenue growth, lasting customer relationships and industry-leading results, in particular leading the successful launch of an extensive number of products for the veterinary industry. He will lead the commercial strategic launch for Zomedica’s diagnostic, point of care and therapeutic product offerings.

Prior to joining Zomedica, Herbst was the Executive Senior Vice President of Sales and Marketing at i4C Innovations. Before that, he served as Executive Senior Director and Head of U.S. Sales at IDEXX Laboratories, where he was responsible for in-clinic and reference lab diagnostics, point of care solutions, and information technologies and digital radiography solutions. Herbst also held commercial leadership roles in patient monitoring, pharmacy and diagnostics with Omnicare Specialty Care Group and Life Systems. He holds a Bachelor of Science in business from the University of Arizona.

Concurrently, Chief Operations Officer Stephanie Morley, DVM, will transition into a dual role of Chief Operations Officer and Vice President of Product Development. Morley will lead the company’s veterinary and innovation strategies, product development activities, research and development, as well as facilitate new business opportunities to ensure the delivery of affordable, high quality veterinary products by aligning customer needs, translational technologies, and corporate objectives.

To further enhance its customer-centric mission, Zomedica recently formed a seven-member veterinary advisory committee comprised of four veterinarians, two licensed veterinary technicians/nurses, and one hospital administrator from various geographic regions across the United States. This committee will function as a dedicated focus group for Zomedica to extend its in-house voice of customer representation with respect to product development, technology evaluation and acquisition, marketing and sales, industry best practices, and more.

Additionally, William C. MacArthur, MS, DVM, has retired as Chief Medical Officer. MacArthur will continue to work as a consultant with Zomedica’s research and development team to advance its therapeutic pipeline.

About Zomedica With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies. With a team comprised of clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com .

Follow Zomedica

• Email Alerts: http://www.zomedica.com/investor-information/
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://www.facebook.com/zomedica/

Reader Advisory Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact Shameze Rampertab, CPA, CA srampertab@zomedica.com +1 647.283.3630 Media Contact Andrea Eberle aeberle@zomedica.com +1 734.369.2555